<DOC>
	<DOCNO>NCT00362973</DOCNO>
	<brief_summary>RATIONALE : Diagnostic procedure , PET scan , may help learn well hormone therapy trastuzumab work kill breast cancer cell allow doctor plan good treatment . PURPOSE : This clinical trial study well PET scan work assess response treatment patient receive hormone therapy trastuzumab breast cancer .</brief_summary>
	<brief_title>PET Scans Assessing Response To Treatment Patients Receiving Hormone Therapy Trastuzumab Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Correlate percent change fludeoxyglucose F 18 ( FDG ) -positron emission tomography ( PET ) standardize uptake value ( SUV ) percent change cell proliferation ( assessed tumor biopsy ) hormonal therapy tumor response patient hormone receptor-positive ( estrogen receptor progesterone receptor ) breast cancer . - Correlate percent change FDG-PET SUV percent change cell proliferation ( assessed tumor biopsy ) treatment trastuzumab ( Herceptin® ) tumor response patient HER-2/neu-positive breast cancer . - Compare association two-week change cell proliferation rate ( measure FDG-PET biopsy ) patient treated aromatase inhibitor trastuzumab . OUTLINE : Patients assign 1 2 group accord therapy . - Group 1 ( patient receive hormonal therapy ) : Patients undergo fludeoxyglucose F 18-positron emission tomography ( FDG-PET ) scan may also undergo 16α-fluoroestradiol F 18 ( FES ) -PET scan baseline ( prior begin therapy ) FDG-PET scan 2 week begin therapy . Blood sample collect baseline 3 6 month begin aromatase inhibitor therapy . The blood sample examine hormone level , include estradiol , estrone , testosterone , follicle-stimulating hormone , sex hormone-binding globulin . - Group 2 ( patient receive HER-2/neu targeted therapy ) : Patients undergo biopsy FDG-PET scan baseline ( prior begin therapy ) FDG-PET scan 1-2 week begin therapy . Some patient undergo core-needle biopsy 2 week begin therapy . Biopsies assess follow marker : proliferative rate ( Ki67 ) , estrogen receptor , progesterone receptor , HER-2/neu , epidermal growth factor receptor , androgen receptor , topoisomerase II . After completion study therapy , patient follow periodically 6 month . PROJECTED ACCRUAL : A total 40 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose breast cancer 1 following : Hormone receptorpositive disease plan receive treatment neoadjuvant aromatase inhibitor ovarian suppression therapy ( premenopausal ) Recurrent and/or metastatic hormone receptorpositive disease plan receive treatment aromatase inhibitor ovarian suppression therapy ( premenopausal ) Metastatic HER2/neupositive disease plan receive treatment neoadjuvant trastuzumab ( Herceptin® ) Recurrent HER2/neupositive disease plan receive treatment trastuzumab ( Herceptin® ) Tumor must accessible biopsy assessable response Tissue block must available review experimental marker patient must willing undergo biopsy Evaluable disease FDGPET scan Available positron emission tomography ( PET ) image clinical indication PET scan May aslo enrol experimental nuclear imaging study 16αfluoroestradiol F 18PET scan ( hormone positive ) Concurrently receive treatment ( hormonal ) breast cancer Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Female male Postmenopausal premenopausal Life expectancy ≥ 2 month No uncontrolled diabetes mellitus comorbidity would preclude image Not pregnant Negative pregnancy test Able tolerate scanning ( e.g. , claustrophobia severe pain ) PRIOR CONCURRENT THERAPY : See Disease Characteristics Concurrent participation another clinical study image study allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>male breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
</DOC>